RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
-23.3%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$275M
AUM Growth
+$275M
(-11%)
Cap. Flow
+$58.7M
Cap. Flow
% of AUM
21.4%
Top 10 Holdings %
Top 10 Hldgs %
72.47%
Holding
42
New
3
Increased
19
Reduced
4
Closed
6
Top Buys
| 1 |
Incyte
INCY
|
$27.5M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$18.4M |
| 3 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
$12.9M |
| 4 |
BLUE
bluebird bio
BLUE
|
$9.4M |
| 5 |
ACHN
Achillion Pharmaceuticals, Inc.
ACHN
|
$4.4M |
Top Sells
| 1 |
Omeros
OMER
|
$14.2M |
| 2 |
DYAX
DYAX CORPORATION
DYAX
|
$4.36M |
| 3 |
KITE
Kite Pharma, Inc.
KITE
|
$3.46M |
| 4 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$1.23M |
| 5 |
Anika Therapeutics
ANIK
|
$1.05M |
Sector Composition
| 1 | Healthcare | 85.06% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Alnylam Pharmaceuticals
ALNY
$58.5B
| $54.4M | 19.74% | 866,379 +293,018 | +51% | +$18.4M |
|
|
2
Incyte
INCY
$16.5B
| $27.5M | 9.98% | +379,415 | New | +$27.5M |
|
|
LJPC
3
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $24.4M | 8.87% | 1,169,065 +84,649 | +8% | +$1.77M |
|
|
ACHN
4
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $19.8M | 7.17% | 2,558,859 +569,945 | +29% | +$4.4M |
|
|
KITE
5
DELISTED
Kite Pharma, Inc.
KITE
| $15.8M | 5.73% | 343,503 -75,432 | -18% | -$3.46M |
|
|
6
Omeros
OMER
$283M
| $13.7M | 4.97% | 891,522 -927,819 | -51% | -$14.2M |
|
|
AVXS
7
DELISTED
AveXis, Inc. Common Stock
AVXS
| $12.9M | 4.68% | +473,374 | New | +$12.9M |
|
|
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $10.9M | 3.94% | 2,026,894 +14,232 | +0.7% | +$76.3K |
|
|
AGEN
9
Agenus
AGEN
$133M
| $10M | 3.65% | 2,414,524 +200,071 | +9% | +$832K |
|
|
BLUE
10
DELISTED
bluebird bio
BLUE
| $9.62M | 3.49% | 226,371 +221,071 | +4,171% | +$9.4M |
|
|
FPRX
11
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $9.22M | 3.35% | 226,998 -30,238 | -12% | -$1.23M |
|
|
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $9.17M | 3.33% | 428,457 +43,001 | +11% | +$920K |
|
|
SSRG
13
DELISTED
SYMMETRY SURGICAL INC COMMON STK
SSRG
| $9.07M | 3.29% | 919,680 +40,057 | +5% | +$395K |
|
14
Atara Biotherapeutics
ATRA
$84.6M
| $9M | 3.27% | 473,126 +39,203 | +9% | +$746K |
|
15
Bristol-Myers Squibb
BMY
$96B
| $7.01M | 2.54% | 109,701 | – | – |
|
16
BioCryst Pharmaceuticals
BCRX
$1.74B
| $5.59M | 2.03% | 1,973,932 -36,569 | -2% | -$103K |
|
17
iShares 20+ Year Treasury Bond ETF
TLT
$47.8B
| $3.92M | 1.42% | +30,000 | New | +$3.92M |
|
18
Celldex Therapeutics
CLDX
$1.47B
| $3.74M | 1.36% | 989,376 +352,138 | +55% | +$1.33M |
|
|
CORI
19
DELISTED
Corium International, Inc.
CORI
| $3.2M | 1.16% | 828,332 +84,467 | +11% | +$326K |
|
|
GBT
20
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $3.03M | 1.1% | 190,981 +15,825 | +9% | +$251K |
|
21
Regenxbio
RGNX
$451M
| $2.61M | 0.95% | 241,323 +19,997 | +9% | +$216K |
|
22
Lipocine
LPCN
$15.8M
| $2.44M | 0.89% | 240,438 +19,923 | +9% | +$202K |
|
|
AXDX
23
DELISTED
Accelerate Diagnostics
AXDX
| $1.68M | 0.61% | 117,176 +9,709 | +9% | +$140K |
|
|
IVTY
24
DELISTED
Invuity, Inc
IVTY
| $1.54M | 0.56% | 212,808 +10,000 | +5% | +$72.2K |
|
25
Masimo
MASI
$7.59B
| $1.08M | 0.39% | 25,900 | – | – |
|